Cisplatin/Vinblastine
- Generic Name
- Cisplatin/Vinblastine
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
- Conditions
- Triple-negative Breast CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- Other: neoadjuvant immuno-chemotherapy
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 54
- Registration Number
- NCT06358573
- Locations
- 🇨🇭
Tumor Zentrum Aarau, Aarau, Switzerland
🇨🇭St. Claraspital, Basel, Switzerland
🇨🇭EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni, Bellinzona, Switzerland
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
- Conditions
- Sarcoma,Soft Tissue
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Intensity Therapeutics, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT06263231
- Locations
- 🇺🇸
Profound Research LLC, Farmington Hills, Michigan, United States
🇩🇪Universitäres Krebszentrum (UCCL), Leipzig, Germany
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 90
- Registration Number
- NCT04781725
- Locations
- 🇨🇦
The Ottawa Hospital Research Institute and Cancer Center, Ottawa, Ontario, Canada
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
- Conditions
- LymphomaLiver CancerColon CancerHead and Neck CancerLung CancerChordoma of SacrumBreast CancerSquamous Cell CarcinomaBile Duct CancerSarcoma
- Interventions
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Intensity Therapeutics, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT03058289
- Locations
- 🇺🇸
USC Norris, Los Angeles, California, United States
🇺🇸USC HOAG, Newport Beach, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.